

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Bayer Global Investments B.V.</u> _____ (Last) (First) (Middle) ENERGIWEG 1 _____ (Street) 3641 RT P7 MIJDRECHT _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/18/2016	3. Issuer Name and Ticker or Trading Symbol <u>CRISPR Therapeutics AG [CRSP]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <input type="checkbox"/>	5. If Amendment, Date of Original Filed (Month/Day/Year) _____ 6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	5,105,330	D ⁽¹⁾	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
			Title	Amount or Number of Shares		

1. Name and Address of Reporting Person* <u>Bayer Global Investments B.V.</u> _____ (Last) (First) (Middle) ENERGIWEG 1 _____ (Street) 3641 RT P7 MIJDRECHT _____ (City) (State) (Zip)
--

1. Name and Address of Reporting Person* <u>BAYER AKTIENGESELLSCHAFT</u> _____ (Last) (First) (Middle) KAISER - WILHEM - ALLEE _____ (Street) 51368 LEVERKUSEN 2M _____ (City) (State) (Zip)
--

Explanation of Responses:

1. Bayer Global Investments B.V. ("Bayer BV") is the Direct Owner of 2,605,330 common shares of CRISPR Therapeutics AG ("CRISPR"). Pursuant to a Subscription Agreement dated December 19, 2015, Bayer BV has agreed to purchase concurrently with the initial public offering of CRISPR in a private placement \$35 million common shares at a price equal to the public offering price of \$14.00, subject to the terms and conditions of the subscription agreement. This Form 3 is a joint filing of Bayer B.V. and Bayer AG. Bayer AG is the 100% Indirect Owner through subsidiaries of the same shares as to which Bayer Global Investments B.V. is the Direct Owner. The Subscription Agreement is incorporated by reference to Exhibit 4.1 of the Form S-1 Registration Statement of CRISPR Dated September 9, 2016.

Remarks:

(2) Exhibit 24: Power of Attorney with respect to Bayer Global Investments B.V.

/s/ Dr. Paul Fort, Attorney-in-
fact on behalf of Bayer Global 10/18/2016
Investments B.V.(2)

/s/ Dr. Paul Fort on behalf of 10/18/2016
Bayer AG

/s/ Dr. Stephan Semrau on 10/18/2016
behalf of Bayer AG

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

(For Executing Form ID and Forms 3, 4 and 5 and Schedules 13D and 13G)

Know all by these presents that the undersigned hereby constitutes and appoints each of Dr. Jan Heinemann, Dr. Paul Fort and Dr. Thomas Reuter, signing individually, the undersigned's true and lawful attorneys-in fact and agents to:

(1) Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the Securities and Exchange Commission of reports required by Sections 13 and 16(a) of the Securities Exchange Act of 1934 or any rule or regulation thereunder;

(2) Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission Forms 3, 4 and 5 and Schedules 13D and 13G (including amendments thereto and joint filing agreements in connection therewith) in accordance with Sections 13 and 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(3) Do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Form 3, 4 or 5 and Schedules 13D and 13G (including amendments thereto and joint filing agreements in connection therewith) and file such Forms and Schedules with the Securities and Exchange Commission and any stock exchange, self-regulatory association or any other authority; and

(4) Take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in the attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned's responsibilities to comply with Sections 13 and 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 and Schedules 13D and 13G with respect to the undersigned's holdings of and transactions in securities issued by CRISPR Therapeutics AG (the "Company"), unless earlier revoked by the undersigned in a signed writing delivered to the Company and the attorneys-in fact. This Power of Attorney revokes any other power of attorney that the undersigned has previously granted with respect to such filings.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below.

Dated: October 12, 2016

Bayer Global Investments B.V.

By: /s/ Axel Steiger-Bagel
Name: Dr. Axel Steiger-Bagel
Title: Managing Director

By: /s/ Adri Koersvelt
Name: Adri Koersvelt
Title: Managing Director